RxDoctor Payments Data

Mary Chao, DO

Internal Medicine · Lansing, MINPI 1881814002

Payments from drug & device makers

$5,739in general payments, 2019–2025

Across 362 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$624
  • Novo Nordisk$623
  • Pfizer$542
  • Novartis$463
  • AbbVie$333
  • GSK$327
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$5,734100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,739 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$57,665
Medicare patients
208
Services billed
699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide190$258,080
EliquisApixaban114$139,903
JardianceEmpagliflozin77$115,209
MounjaroTirzepatide81$100,363
JanuviaSitagliptin Phosphate57$75,552
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$70,590
TrulicityDulaglutide45$67,946
RybelsusSemaglutide34$59,609
FarxigaDapagliflozin Propanediol39$51,438
LinzessLinaclotide40$38,829
XareltoRivaroxaban22$32,412
Tresiba Flextouch U-100Insulin Degludec32$25,320
GemtesaVibegron38$24,201
ProliaDenosumab14$23,912
EntrestoSacubitril/Valsartan21$22,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$623$317,689224 claims
Lilly USA, LLCMounjaro, Trulicity$624$168,308126 claims
PfizerEliquis, Premarin$542$153,624142 claims
Boehringer IngelheimJardiance, Tradjenta$265$135,694104 claims
MerckJanuvia$269$75,55257 claims
GSKTrelegy Ellipta$327$70,59069 claims
AstraZenecaFarxiga, Symbicort$170$55,81950 claims
AbbVieLinzess, Synthroid$333$47,119118 claims
Johnson & JohnsonXarelto$190$32,41222 claims
Sumitomo Pharma America, Inc.Gemtesa$50$24,20138 claims
AmgenProlia$205$23,91214 claims
NovartisEntresto$463$22,79121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →